However, due to the interaction between SPARC and albumin-bound drugs, SPARC overexpression may be predictive of improved outcomes following treatment with nab-paclitaxel in head and neck cancer and advanced pancreatic cancer [44, 45], although this correlation was not found in NSCLC cell lines [46]. The gene discussed is SPARC; the disease is non-small cell lung carcinoma.